Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Accolade, Inc. (NASDAQ: ACCD) has announced its upcoming Analyst Day event scheduled for May 8, 2023, at the Wynn Las Vegas. The event will start at 1pm PT and will be available via a live webcast for pre-registered attendees. During the event, Accolade’s management will share insights into the company’s long-term vision, along with details on its product, clinical, ecosystem, and financial strategies. Interested participants can register through ir.accolade.com. A replay of the event will also be accessible after the live session.
Accolade focuses on providing personalized healthcare solutions to millions, ensuring high consumer satisfaction ratings exceeding 90%. For more information, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) announced that it will release its fiscal fourth quarter 2023 financial results on April 27, 2023, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss the results.
The call will be accessible via telephone or internet, with pre-registration required for the phone option. A replay will be available shortly after the call concludes. Accolade specializes in personalized healthcare solutions, enhancing healthcare experiences for millions through virtual primary care, mental health services, and care navigation.
The company consistently achieves over 90% consumer satisfaction ratings, reflecting its commitment to improving healthcare delivery.
Accolade, Inc. (Nasdaq: ACCD) has partnered with Lyra Health to enhance behavioral health care access for employers. This collaboration, part of Accolade's Trusted Partner Ecosystem, aims to address the barriers faced by U.S. workers in accessing mental health services. A recent Gallup survey revealed over half of workers lack awareness of available resources. Lyra Health provides evidence-based services, aiming for prompt access with an average wait time of only two days for appointments. The partnership promises improved mental health support for joint customers without additional costs.